Journal of Shandong University (Health Sciences) ›› 2026, Vol. 64 ›› Issue (4): 117-124.doi: 10.6040/j.issn.1671-7554.0.2025.1013
• Review • Previous Articles
LIN Mingxia, LIU Guibin, MA Yanhua, LIAN Zhaoyu, REN Yangyang
CLC Number:
| [1] Lutsenko S, Roy S, Tsvetkov P. Mammalian copper homeostasis: physiological roles and molecular mechanisms[J]. Physiol Rev, 2025, 105(1): 441-491. [2] Wang YF, Hodgkinson V, Zhu S, et al. Advances in the understanding of mammalian copper transporters[J]. Adv Nutr, 2011, 2(2): 129-137. [3] Kuo MT, Chen HHW, Song IS, et al. The roles of copper transporters in cisplatin resistance[J]. Cancer Metastasis Rev, 2007, 26(1): 71-83. [4] Howell SB, Safaei R, Larson CA, et al. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs[J]. Mol Pharmacol, 2010, 77(6): 887-894. [5] Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261. [6] Shan D, Song JL, Ren YQ, et al. Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities[J]. Cancer Commun, 2025, 45(5): 577-607. [7] 陈蕾洁, 刘德良, 谭玉勇. 铜死亡在肝癌中的研究进展[J]. 中南大学学报(医学版), 2023, 48(9): 1368-1376. CHEN Leijie, LIU Deliang, TAN Yuyong. Research progress in cuproptosis in liver cancer[J]. J Cent South Univ(Med Sci), 2023, 48(9): 1368-1376. [8] Festa RA, Thiele DJ. Copper: an essential metal in biology[J]. Curr Biol, 2011, 21(21): R877-R883. [9] Tsang T, Davis CI, Brady DC. Copper biology[J]. Curr Biol, 2021, 31(9): R421-R427. [10] Steensholt G. On the effect of copper on cytochrome oxidase[J]. Acta Physiol Scand, 1947, 14(4): 335-339. [11] Robinett NG, Peterson RL, Culotta VC. Eukaryotic copper-only superoxide dismutases(SODs): a new class of SOD enzymes and SOD-like protein domains[J]. J Biol Chem, 2018, 293(13): 4636-4643. [12] Prigge ST, Mains RE, Eipper BA, et al. New insights into copper monooxygenases and peptide amidation: structure, mechanism and function[J]. Cell Mol Life Sci, 2000, 57(8/9): 1236-1259. [13] Wang HL, Poe A, Pak L, et al. An in situ activity assay for lysyl oxidases[J]. Commun Biol, 2021, 4(1): 840. doi:10.1038/s42003-021-02354-0 [14] Bielli P, Calabrese L. Structure to function relationships in ceruloplasmin: a "moonlighting" protein[J]. Cell Mol Life Sci, 2002, 59(9): 1413-1427. [15] Samygina VR, Sokolov AV, Bourenkov G, et al. Ceruloplasmin: macromolecular assemblies with iron-containing acute phase proteins[J]. PLoS One, 2013, 8(7): e67145. doi:10.1371/journal.pone.006714 [16] Prasad AS, Brewer GJ, Schoomaker EB, et al. Hypocupremia induced by zinc therapy in adults[J]. JAMA, 1978, 240(20): 2166-2168. [17] Hasan NM, Gupta A, Polishchuk E, et al. Molecular events initiating exit of a copper-transporting ATPase ATP7B from the trans-Golgi network[J]. J Biol Chem, 2012, 287(43): 36041-36050. [18] Petris MJ, Mercer JF, Culvenor JG, et al. Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking[J]. EMBO J, 1996, 15(22): 6084-6095. [19] La Fontaine S, Mercer JFB. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis[J]. Arch Biochem Biophys, 2007, 463(2): 149-167. [20] Turnlund JR. Human whole-body copper metabolism[J]. Am J Clin Nutr, 1998, 67(5 Suppl): 960S-964S. [21] Lv PP, Man SL, Xie L, et al. Pathogenesis and therapeutic strategy in platinum resistance lung cancer[J]. BiochimBiophys Acta Rev Cancer, 2021, 1876(1): 188577. doi:10.1016/j.bbcan.2021.188577 [22] Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer[J]. Drug Resist Updat, 2016, 24: 23-33. doi:10.1016/j.drup.2015.11.004 [23] Fodor I, Yañez-Guerra LA, Kiss B, et al. Copper-transporting ATPases throughout the animal evolution-from clinics to basal neuron-less animals[J]. Gene, 2023, 885: 147720. doi:10.1016/j.gene.2023.147720 [24] Tümer Z, Møller LB. Menkes disease[J]. Eur J Hum Genet, 2010, 18(5): 511-518. [25] Kim JH, Lee BH, Kim YM, et al. Novel mutations and clinical outcomes of copper-histidine therapy in Menkes disease patients[J]. Metab Brain Dis, 2015, 30(1): 75-81. [26] De Feyter S, Beyens A, Callewaert B. ATP7A-related copper transport disorders: a systematic review and definition of the clinical subtypes[J]. J Inherit Metab Dis, 2023, 46(2): 163-173. [27] Wu ZX, Lv GS, Xing FX, et al. Copper in hepatocellular carcinoma: a double-edged sword with therapeutic potentials[J]. Cancer Lett, 2023, 571: 216348. doi:10.1016/j.canlet.2023.216348 [28] Yan J, Zhang HL, Zhang MT, et al. The association between trace metals in both cancerous and non-cancerous tissues with the risk of liver and gastric cancer progression in Northwest China[J]. J Pharm Biomed Anal, 2024, 242: 116011. doi:10.1016/j.jpba.2024.116011 [29] Feng Y, Zeng JW, Ma Q, et al. Serum copper and zinc levels in breast cancer: a meta-analysis[J]. J Trace Elem Med Biol, 2020, 62: 126629. doi:10.1016/j.jtemb.2020.126629 [30] Wang WJ, Wang X, Luo JJ, et al. Serum copper level and the copper-to-zinc ratio could be useful in the prediction of lung cancer and its prognosis: a case-control study in Northeast China[J]. Nutr Cancer, 2021, 73(10): 1908-1915. [31] Blockhuys S, Celauro E, Hildesjö C, et al. Defining the human copper proteome and analysis of its expression variation in cancers[J]. Metallomics, 2017, 9(2): 112-123. [32] Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease[J]. Biochem J, 1984, 219(1): 1-14. [33] Almeida da Silva D, De Luca A, Squitti R, et al. Copper in tumors and the use of copper-based compounds in cancer treatment[J]. J Inorg Biochem, 2022, 226: 111634. doi:10.1016/j.jinorgbio.2021.111634 [34] Das A, Ash D, Fouda AY, et al. Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis[J]. Nat Cell Biol, 2022, 24(1): 35-50. [35] Martin F, Linden T, Katschinski DM, et al. Copper-dependent activation of hypoxia-inducible factor(HIF)-1: implications for ceruloplasmin regulation[J]. Blood, 2005, 105(12): 4613-4619. [36] Shao K, Shen H, Chen XF, et al. Copper transporter gene ATP7A: a predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma[J]. Int Immunopharmacol, 2023, 114: 109518. doi:10.1016/j.intimp.2022.109518 [37] Shi ZM, Mao ZY, Cui M, et al. ATP7A as a prognostic biomarker and potential therapeutic target in gastric cancer[J]. Am J Transl Res, 2025, 17(1): 512-527. [38] Yu Z, Cao WF, Ren Y, et al. ATPase copper transporter A, negatively regulated by miR-148a-3p, contributes to cisplatin resistance in breast cancer cells[J]. Clin Transl Med, 2020, 10(1): 57-73. [39] Zhang SY, Liu XY, Zhang JQ, et al. Cancer-associated fibroblasts promote oral squamous cell carcinoma progression by targeting ATP7A via exosome-mediated paracrine miR-148b-3p[J]. Cell Signal, 2025, 128: 111631. doi:10.1016/j.cellsig.2025.111631 [40] Sha SN, Si LY, Wu XR, et al. Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer[J]. Front Immunol, 2022, 13: 922780. doi:10.3389/fimmu.2022.922780 [41] Shimada K, Reznik E, Stokes ME, et al. Copper-binding small molecule induces oxidative stress and cell-cycle arrest in glioblastoma-patient-derived cells[J]. Cell Chem Biol, 2018, 25(5): 585-594. [42] Yip NC, Fombon IS, Liu P, et al. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties[J]. Br J Cancer, 2011, 104(10): 1564-1574. [43] Chan N, Willis A, Kornhauser N, et al. Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases[J]. Clin Cancer Res, 2017, 23(3): 666-676. [44] Xie JM, Yang YN, Gao YB, et al. Cuproptosis: mechanisms and links with cancers[J]. Mol Cancer, 2023, 22(1): 46. doi:10.1186/s12943-023-01732-y [45] Liu HR, Tang T. Pan-cancer genetic analysis of cuproptosis and copper metabolism-related gene set[J]. Front Oncol, 2022, 12: 952290. doi:10.3389/fonc.2022.952290 [46] Nagai M, Vo NH, Shin Ogawa L, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells[J]. Free Radic Biol Med, 2012, 52(10): 2142-2150. [47] Gao W, Huang Z, Duan JF, et al. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A[J]. Mol Oncol, 2021, 15(12): 3527-3544. [48] Wangpaichitr M, Sullivan EJ, Theodoropoulos G, et al. The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells[J]. Mol Cancer Ther, 2012, 11(3): 604-615. [49] Monk BJ, Kauderer JT, Moxley KM, et al. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: an NRG oncology/gynecologic oncology group study[J]. Gynecol Oncol, 2018, 151(3): 422-427. [50] ODay S, Gonzalez R, Lawson D, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma[J]. J Clin Oncol, 2009, 27(32): 5452-5458. [51] Hedley D, Shamas-Din A, Chow S, et al. A phase I study of elesclomol sodium in patients with acute myeloid leukemia[J]. Leuk Lymphoma, 2016, 57(10): 2437-2440. [52] Li ZH, Li SW, Wen YQ, et al. miR-495 inhibits cisplatin resistance and angiogenesis in esophageal cancer by targeting ATP7A[J]. Technol Cancer Res Treat, 2021, 20: 15330338211039127. doi:10.1177/15330338211039127 [53] Zhou Y, Zhang Q, Wang MJ, et al. Effective delivery of siRNA-loaded nanoparticles for overcoming oxaliplatin resistance in colorectal cancer[J]. Front Oncol, 2022, 12: 827891. [54] Guan M, Cheng K, Xie XT, et al. Regulating copper homeostasis of tumor cells to promote cuproptosis for enhancing breast cancer immunotherapy[J]. Nat Commun, 2024, 15(1): 10060. doi:10.1038/s41467-024-54469-7 [55] Wu XY, Bai ZJ, Wang H, et al. CRISPR-Cas9 gene editing strengthens cuproptosis/chemodynamic/ferroptosis synergistic cancer therapy[J]. Acta Pharm Sin B, 2024, 14(9): 4059-4072. [56] Chaudhary A, Kumar A, Ankit A, et al. Discovery of Cu(II)-dipyridophenazine complex for synergistic cuproptosis/chemodynamic therapy via disrupting the tricarboxylic acid(TCA)cycle in metastatic TNBC[J]. Small, 2025, 21(26): e2504554. doi:10.1002/smll.202504554 [57] Chang J, Yin WM, Zhi H, et al. Copper deposition in polydopamine nanostructure to promote cuproptosis by catalytically inhibiting copper exporters of tumor cells for cancer immunotherapy[J]. Small, 2024, 20(27): e2308565. doi:10.1002/smll.202308565 [58] Gao Y, Han RL, Guo Z, et al. Multi-pathway copper metabolisms regulation based on an engineered copper/ferrous nanoplatform for enhanced tumor cuproptosis therapy[J]. Colloids Surf B Biointerfaces, 2025, 252: 114682. doi:10.1016/j.colsurfb.2025.114682 [59] Mandana AM, Melika AM, Parvin S. Cinobufagin treatments suppress tumor growth by enhancing the expression of cuproptosis-related genes in liver cancer[J]. NaunynSchmiedebergs Arch Pharmacol, 2025, 398(2): 1575-1582. [60] Xiao YX, Yin JM, Liu P, et al. Triptolide-induced cuproptosis is a novel antitumor strategy for the treatment of cervical cancer[J]. Cell Mol Biol Lett, 2024, 29(1): 113. doi:10.1186/s11658-024-00623-4 [61] Yu H, Wang HD, Qie AR, et al. FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect[J]. Cancer Sci, 2021, 112(11): 4655-4668. |
| [1] | GE Li-Juan, JIN Rui-Feng, WANG Ji-Wen, HU Xin-Sheng, LIKun. Association between the C1236T polymorphism in multi-drug resistance gene 1 and response to antiepileptic drug treatment in epileptic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 99-102. |
| [2] | LIU Chao, DIAO Tingting, ZHANG Hongji, LIU Hongwei, YANG Yongrui, LI Xiaofei. Application value of matrix-assisted laser desorption ionization time-of-flight mass spectrometry in the detection of drug resistance of Mycobacterium tuberculosis [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 61-67. |
| [3] | LIU Na, WANG Nana, JI Bing, DING Xuemei, LIU Yaxin, FANG Xiaoqing, ZHANG Xiaoli. Distribution and drug resistance changes of pathogenic bacteria in hospitalized elderly inpatients from 2012 to 2021 [J]. Journal of Shandong University (Health Sciences), 2023, 61(6): 29-40. |
| [4] | JIN Xinjuan, ZUO Liping, DENG Zhanhao, LI Anning, YU Dexin. Value of enhanced MRI radiomics in predicting the drug-resistant protein PFKFB3 in 135 cases of hepatocellular carcinoma [J]. Journal of Shandong University (Health Sciences), 2023, 61(6): 79-86. |
| [5] | ZHAO Kai, YIN Xinbao, ZHANG Zongliang, WANG Zhenlin, ZHU Guanqun, WANG Ke. Inhibitory effect and mechanism of astragaloside Ⅱ on renal clear cell carcinoma cells [J]. Journal of Shandong University (Health Sciences), 2023, 61(1): 10-16. |
| [6] | LI Yan, LIU Jing, LI Juan, YANG Qiuhong. Clinical characteristics and placental pathology of bloodstream infection in 50 pregnant women [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 48-54. |
| [7] | JU Jianhua, YANG Zhenye, LI Qinglian, HAN Yanan, LI Yanqing, QIAO Yijun, YANG Hu, ZHANG Huaran. Advances on drugs derived from microbial sources and future perspectives [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 43-50. |
| [8] | HA Chunfang, LI Ruyue. Research progress of drug resistance in ovarian cancer and targeted therapy strategy [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 117-123. |
| [9] | XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110. |
| [10] | FU Zhenmei, MA Mingze. Expression of P-glycoprotein in the colonic mucosa of ulcerative colitis patients and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 54-59. |
| [11] | ZHANG Ning, YANG Yan, LI Rui, YIN Yunhong, LI Hao, QU Yiqing. Analysis of risk factors and drug resistance of Acinetobacter baumannii in patients with chronic obstructive pulmonary disease [J]. Journal of Shandong University (Health Sciences), 2019, 57(9): 88-96. |
| [12] | WANG Chuanxin. Research progress of exosomes biomarkers in tumor development [J]. Journal of Shandong University (Health Sciences), 2018, 56(10): 18-23. |
| [13] | MENG Wei, WU Dawei, SHAN Tichao, ZHANG Fan, GUO Haipeng, LIU Yu, DING Shifang, ZHAI Qian. Tigecycline in treating ventilator-associated pneumonia in critically ill patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 71-75. |
| [14] | YUAN Yuan, SI Heng, LIU Hongwei, LIU Chunhua, WANG Zhe, RUAN Yuhua, XING Hui. HIV drug resistance and the impact of antiretroviral therapy initiated at different stages among AIDS patiens [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 77-81. |
| [15] | LIU Qiong, PU Yedi, DAI Guangxia, MA Jiale, YANG Jianxia, LI Lizhen, LI Hao, WANG Luqun. A microarray analysis of bortezomib-resistant gene expression in multiple myeloma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(6): 33-38. |
|
||
